The SINUVA™ sinus implant is a new in-office treatment option for recurring nasal polyps. New technology provides sustained relief for managing chronic condition.
Nasal polyps are benign growths that can form in the lining of the nose and are estimated to impact millions of people throughout the US. These polyps can obstruct air, cause facial pain, and can result in a total or partial loss of a person’s sense of taste and smell.
Many people with recurring polyps are referred by their doctor to an ear, nose, and throat specialist. ENT specialists have traditionally treated nasal polyps by performing surgical procedures or prescribing high-dose oral steroids and intranasal sprays. Surgical options may not treat the issue permanently and oral steroids and intranasal sprays often require people to remember to take medications every day. A new solution was needed.
Intersect ENT has developed the SINUVA™ (mometasone furoate) Sinus Implant. The SINUVA Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ?18 years of age who have had ethmoid sinus surgery
The SINUVA™ implant, which can be easily inserted during a routine office visit, expands in the sinus cavity, delivering a steroid directly to the sinus for up to 90 days. SINUVA™ softens over time and can be removed at 90 days or earlier at the physician’s discretion. This innovative delivery system has been approved by the FDA to treat nasal polyps in adults who have had previous ethmoid sinus surgery (ESS).
SINUVA™ Sinus Implant is a prescription steroid-releasing (mometasone furoate) implant indicated for the treatment of nasal polyps in patients 18 years or older who have had ethmoid sinus surgery.